Rafferty Asset Management
TGTX icon

Rafferty Asset Management’s TG Therapeutics TGTX Stock Holding History

Rafferty Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.25M Sell
59,212
-101,590
-63% -$4.16M 0.01% 516
2026
Q1 		$5.34M Sell
160,802
-29,310
-15% -$873K 0.02% 340
2025
Q4 		$5.67M Sell
190,112
-21,946
-10% -$717K 0.02% 400
2025
Q3 		$7.66M Buy
212,058
+23,838
+13% +$785K 0.02% 340
2025
Q2 		$6.77M Buy
188,220
+6,359
+3% +$237K 0.02% 340
2025
Q1 		$7.17M Sell
181,861
-149,551
-45% -$5.03M 0.03% 307
2024
Q4 		$9.98M Sell
331,412
-9,057
-3% -$260K 0.04% 290
2024
Q3 		$7.96M Buy
340,469
+3,505
+1% +$76.5K 0.03% 318
2024
Q2 		$5.99M Sell
336,964
-209,555
-38% -$3.34M 0.02% 380
2024
Q1 		$8.31M Sell
546,519
-24,607
-4% -$392K 0.03% 337
2023
Q4 		$9.75M Sell
571,126
-285,711
-33% -$3.32M 0.04% 287
2023
Q3 		$7.16M Buy
856,837
+554,309
+183% +$7.73M 0.04% 315
2023
Q2 		$7.51M Sell
302,528
-180,507
-37% -$4.66M 0.04% 309
2023
Q1 		$7.26M Sell
483,035
-268,744
-36% -$4.08M 0.05% 279
2022
Q4 		$8.89M Sell
751,779
-21,431
-3% -$156K 0.07% 215
2022
Q3 		$4.58M Buy
773,210
+161,805
+26% +$1.06M 0.05% 348
2022
Q2 		$2.6M Buy
611,405
+3,780
+0.6% +$23.6K 0.02% 416
2022
Q1 		$5.78M Buy
607,625
+289,391
+91% +$3.35M 0.03% 344
2021
Q4 		$6.05M Buy
318,234
+213,638
+204% +$5.55M 0.03% 299
2021
Q3 		$3.48M Buy
104,596
+35,537
+51% +$1.1M 0.02% 402
2021
Q2 		$2.68M Buy
69,059
+2,195
+3% +$86.2K 0.02% 550
2021
Q1 		$3.22M Buy
66,864
+44,811
+203% +$2.15M 0.02% 439
2020
Q4 		$1.15M Sell
22,053
-57,600
-72% -$1.95M 0.01% 473
2020
Q3 		$2.13M Buy
79,653
+24,096
+43% +$554K 0.03% 398
2020
Q2 		$1.08M Buy
55,557
+44,830
+418% +$722K 0.02% 522
2020
Q1 		$106K Sell
10,727
-80,336
-88% -$1.01M ﹤0.01% 556
2019
Q4 		$1.01M Sell
91,063
-142,277
-61% -$1.08M 0.02% 550
2019
Q3 		$1.31M Sell
233,340
-79,433
-25% -$554K 0.02% 483
2019
Q2 		$2.71M Buy
312,773
+160,887
+106% +$1.22M 0.05% 283
2019
Q1 		$1.22M Buy
+151,886
New +$821K 0.02% 511

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Rafferty Asset Management's TGTX Position: Q2 2026 in Review

Rafferty Asset Management reduced its TG Therapeutics (TGTX) stake by 63% in Q2 2026, selling an estimated $4.16M and leaving 59,212 shares worth $3.25M. The position accounts for 0.01% of the portfolio, ranked #516.

Rafferty Asset Management first reported a position in TGTX in Q1 2019 and has held it in 30 quarters since. The position peaked at $9.98M in Q4 2024. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Rafferty Asset Management held 59,212 shares of TG Therapeutics worth $3.25M as of Q2 2026.
  • Rafferty Asset Management sold 101,590 TG Therapeutics shares in Q2 2026, an estimated $4.16M.
  • TG Therapeutics made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #516 holding.
  • Rafferty Asset Management first reported a position in TG Therapeutics in Q1 2019 and has held it in 30 quarters since.
  • Rafferty Asset Management's TG Therapeutics position peaked at $9.98M in Q4 2024.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.